Telavancin’s “Complete Response” Letter Calls For Pregnancy-Focused REMS

Theravance is the last of the three sponsors from a marathon advisory committee review of antibiotics for cSSSI to get an action letter; as the only one with a positive vote, it’s the only one that doesn’t need further trials.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet